The latest publication on Avemar was published at the Nutritional Journal. According to the study, the intensified preclinical and clinical research resulting in the characterization of several mechanisms of action, provided evidence for potential versatile clinical activity. The review gives an excellent summary on the available research conducted with Avemar. In conclusion FWGE has an interesting preclinical and clinical activity profile with no toxicity. The use of FWGE as a non-prescription medical nutriment for cancer patients seems maintainable and combined use with chemotherapy appears feasible.
Read the full article at: www.research.avemar.com